Metformin prevents ischemia reperfusion-induced oxidative stress in the fatty liver by attenuation of reactive oxygen species formation

Monika Cahova¹, Eliska Palenickova¹,², Helena Dankova¹, Eva Sticova³, Martin Burian⁴, Zdenek Drahota⁵, Zuzana Cervinkova⁶, Otto Kucera⁶, Christina Gladkova⁷, Pavel Stopka⁸, Jana Krizova⁸, Zuzana Papackova¹, Olena Oliyarnyk¹, Ludmila Kazdova¹

¹Center for Experimental Medicine, Department of Metabolism and Diabetes; ²Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic; ³Clinical and Transplant Pathology Department; ⁴Department of Diagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, CR; ⁵Institute of Physiology, Czech Academy of Sciences, Prague, CR; ⁶Department of Physiology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Hradec Kralove, CR; ⁷Department of Chemistry, University of Cambridge, Cambridge, United Kingdom; ⁸Institute of Inorganic Chemistry AS CR, Husinec-Rez, CR.

Running title: Antioxidant effects of metformin in the fatty liver

Monika Cahova and Eliska Palenickova contributed equally to this work.

Corresponding author: Monika Cahova, Institute for Clinical and Experimental Medicine, Department of Metabolism and Diabetes, Videnska 1958/9, Prague 4, 14021, Czech Republic, phone +420261365366, fax +420261363027, e-mail monika.cahova@ikem.cz

Copyright © 2015 by the American Physiological Society.
Non-alcoholic fatty liver disease is associated with chronic oxidative stress. In our study, we explored the antioxidant effect of antidiabetic metformin on chronic (high-fat diet-induced, HFD) and acute oxidative stress induced by short-term warm partial ischemia/reperfusion (I/R) or on a combination of both in the liver. Wistar rats were fed a standard diet (SD) or HFD for 10 weeks, half of them being administered metformin (150 mg.kg⁻¹ b.wt. per day). Metformin treatment prevented acute stress-induced necroinflammatory reaction, reduced ALT and AST serum activity and diminished lipoperoxidation. The effect was more pronounced in the HFD than in the SD group. The metformin-treated groups exhibited less severe mitochondrial damage (markers: cytochrome c release, citrate synthase activity, mtDNA copy number, mitochondrial respiration) and apoptosis (caspase 9 and caspase 3 activation). Metformin-treated HFD-fed rats subjected to I/R exhibited increased antioxidant enzyme activity as well as attenuated mitochondrial respiratory capacity and ATP re-synthesis. The exposition to I/R significantly increased NADH- and succinate-related reactive oxygen species (ROS) mitochondrial production in vitro. The effect of I/R was significantly alleviated by previous metformin treatment. Metformin down-regulated the I/R-induced expression of pro-inflammatory (TNFα, TLR4, IL1-β, Ccr2) and infiltrating monocyte (Ly6c) and macrophage (CD11b) markers. Our data indicate that metformin reduces mitochondrial performance but concomitantly protects the liver from I/R-induced injury. We propose that the beneficial effect of metformin action is based on a combination of three contributory mechanisms: increased antioxidant enzyme activity, lower mitochondrial ROS production and reduction of post-ischemic inflammation.

**Key words**

Metformin, oxidative stress, mitochondrial respiration, liver injury, $^{31}$P MR spectroscopy
Metformin is an oral antihyperglycemic drug widely used in the treatment of type 2 diabetes (T2D) (7). There is evidence that metformin also protects against oxidative stress in various tissues, although the antioxidant activity of metformin is not well understood. It has been shown that hyperglycemia is associated with increased reactive oxygen species (ROS) formation due to superoxide overproduction from the mitochondrial electron transport chain as a consequence of increased glycolysis (8). It has been hypothesized that the antioxidative effect of metformin is simply the consequence of its glucose-lowering effect and subsequent decrease in superoxide anion production (3). Nevertheless, metformin has also displayed antioxidative characteristics in several models of oxidative stress without hyperglycemia (2,19,20,21,62).

Increased production and/or ineffective scavenging of ROS play an important role in the pathogenesis of many diabetic complications (14). Non-alcoholic fatty liver disease, a component of a cluster of pathophysiological conditions preceding the manifestation of overt T2D, is often associated with chronic oxidative stress. Surprisingly, there are not much data regarding the effect of metformin on oxidative stress in the fatty liver in the context of insulin resistance. Liver ischemia reperfusion (I/R) injury is a major contributor to tissue damage during liver transplantation, liver resection procedures, hypovolemic shock, and trauma. It is a major cause of primary non-function after liver transplantation (11). I/R injury is a phenomenon in which damage to a hypoxic organ is accentuated following the return of oxygen delivery. The immediate response involves the disruption of the cellular mitochondrial oxidative phosphorylation and accumulation of metabolic intermediates during the ischemic period and oxidative stress following the resumption of blood flow (42). As a result, a direct cellular damage occurs due to the ROS impact on lipids and other biomacromolecules. Moreover, oxidative stress impairs mitochondrial function which leads to further production of ROS and amplification of oxidative stress and tissue injury (37). ROS produced during oxidative stress may also act as
signaling molecules, which activate inflammatory pathways and which in turn accentuate primary injury (32). Thus, the extent of early ROS formation represents a critical event in terms of the magnitude of the final injury.

The aim of our study was to assess the effect of metformin on both chronic oxidative stress induced by high-fat feeding (HFD), acute stress caused by short-term warm I/R or on the combination of both. We recorded the effects of metformin on whole body, tissue and cellular levels. We further focused on the possible mechanisms of metformin antioxidant action, particularly on those related to metformin interaction with the mitochondrial respiratory chain, ROS production and inflammatory processes.

Materials and Methods

Animals and experimental design

Male Wistar rats aged 4 months were kept in a temperature-controlled environment with a 12h light/dark cycle on either SD (protein 33cal%, starch 58cal%, fat 9cal%) or HFD (protein 28cal%, starch 12cal%, fat 60cal%) diets. Half of the animals in both groups were provided metformin in a dose of 150 mg.kg\(^{-1}\) b.wt. for 10 weeks by gavage. This dose corresponds to a human dose of 15mg/kg/day, according to the normalization of body surface area (18) and results in comparable serum metformin concentrations (1-10 µM). The animals in groups labeled I/R (ischemia reperfusion) were subjected to short-term (20 min) warm partial ischemia induced during anesthesia by portal vein ligation. After restoration of circulation, the abdominal cavity was closed and animals were left to recover 48 hours prior to decapitation. Sham-operated animals were subjected only to the opening of the abdominal cavity without portal vein ligation. All experiments were performed in accordance with the Animal Protection Law of the Czech Republic 311/1997, which is in compliance with the Principles of Laboratory Animal Care (NIH
5

Guide to the Care and Use of Laboratory Animals, 8th edition, 2013) and were approved by the Ethical Committee of IKEM.

Histological evaluation of liver injury
Liver tissue was fixed in 4% paraformaldehyde, embedded in paraffin blocks and routinely processed. Sections cut at 4-6 µm were stained with hematoxylin/eosin and examined with an Olympus BX41 light microscope.

Electrophoretic separation and immunodetection
The homogenate and post-mitochondrial fractions were prepared from freshly excised liver tissue. The protein concentration was determined using the BCA method (Thermo Scientific, Waltham, MA). The proteins were separated by electrophoretic separation under denaturing conditions and electroblotted to PVDF membranes. Proteins of interest were detected using specific antibodies (cytochrome c: ab53056 Abcam, Cambridge, UK; caspase 3: #9662, caspase 9: #9506, Cell Signaling, MA, USA). The loading control was performed using rabbit polyclonal antibody to beta actin (ab 8227, Abcam, Cambridge, UK). Bands were visualized using ECL and quantified using the FUJI LAS-3000 imager (FUJI FILM, Japan) and Quantity One software (Biorad, Hercules, CA).

Citrate synthase specific activity
Citrate synthase (CS) activity was measured according to Rustin, et al. (52). Briefly, the cells were lysed with 1% lauryl maltoside and CS activity was measured according to the conversion of acetyl-CoA and oxaloacetate to citrate and CoA-SH. This rate-limiting reaction catalyzed by CS was coupled to the irreversible reduction of chromogenic substrate TNB (thionitrobenzoic
acid). Citrate synthase activity was measured as an increase of absorbance at 412 nm per time interval (1 min) and was related to the total content of protein determined by the BCA Protein Assay Reagent (Thermo Scientific).

**mtDNA copy number estimation**

mtDNA copy number per cell was quantified as the ratio of mitochondrial DNA to nuclear DNA as previously described (70). In brief, quantitative PCR analysis using SYBR green (Solid Biodyne, Estonia) was performed with 25 μg of isolated DNA (Qiagen). Mitochondrial DNA was assessed according to the expression of mitochondrial-encoded Nd5 gene. Nuclear DNA level was determined by amplifying the genomic Ucp2. The relative amount of mitochondrial to nuclear DNA was determined by normalized Nd5 to Ucp2 levels.

**Isolation of liver mitochondria and preparation of submitochondrial particles**

Liver mitochondria were prepared by differential centrifugation as described by Bustamante, et al. (10) with some modifications. Rat liver tissue was homogenized at 0 °C using a teflon-glass homogenizer as a 10 % homogenate in a medium containing 220 mM mannitol, 70 mM sucrose and 1 mM HEPES, pH 7.2 (MSH medium). Crude impurities were removed by centrifugation at 800 g, 10 min, and the remaining supernatant was centrifuged for 10 min at 8 000 g. Pelleted mitochondria were re-suspended in the MSH medium, washed twice via 10 min centrifugation at 8 000 g and finally re-suspended in a concentration of 20-30 mg protein/ml. Mitochondrial proteins were determined using the BCA method (Thermo Scientific, Waltham, MA). In order to determine ROS production, submitochondrial particles (SMP) were prepared according to Ide (27). Briefly, the isolated mitochondria were sonicated and pelleted by centrifugation at 21 000 g,
10 min. The resultant pellet was washed three times in MSH buffer in order to get rid of matrix components and stored at -80°C.

Measurement of mitochondrial respiration using the Seahorse technique

An XF 24 extracellular flux analyzer was used to determine mitochondrial function (XF 24, Seahorse Bioscience, http://www.seahorsebio.com/company/about.php). The validity of this method in comparison to classical Clark electrode oxygraph measurements has been proved recently (22). Freshly isolated liver mitochondria (10 µg per well) in 50 µl of MAS buffer (220 mM mannitol, 70 mM sucrose, 10 mM KH₂PO₄, 5. 5 mM MgCl₂, 2 mM HEPES, 1 mM EGTA, pH 7.4) were delivered to each well on ice and the 24well plate was centrifuged at 20 000 g for 20 min at 4°C in order to enhance the attachment of the mitochondria to the plastic. After centrifugation, 450 µl of pre-warmed MAS buffer was added to each plate and the first two measurements were performed in the absence of any added substrate. Subsequently, the following substances were added in the indicated order (final concentrations): 10 mM glutamate + 5 mM malate; 4 mM ADP; 2 µM rotenone; 10 mM succinate. The data are given as the oxygen consumption rate (OCR) in pmoles O₂/min.

Parameters of oxidative stress

The activities of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase 1 (GPx1) and thiobarbituric acid reactive substances (TBARS) content were determined as described previously (50). The content of reduced GSH was determined using the Glutathione HPLC diagnostic kit (Chromsystems, Munich, Germany), 4-hydroxynonenal (4-HNE) concentration by OxiSelect™ HNE Adduct Competitive ELISA Kit (Cell Biolabs, San Diego, CA).
Fluorometric determination of reactive oxygen species production

ROS production in SMPs in vitro was measured using a DCFDA (Cell Biolabs, San Diego, CA) probe as described previously (67). Briefly, the assay was performed with approx. 0.2 mg of mitochondrial protein per ml in an MAS buffer supplemented with either 10 mM NADH, 10 mM glycerol phosphate (sn-glycerol 3-phosphate) or 10 mM succinate. The final concentration of DCFDA was 10 µM and the excitation/emission wavelength was 485/528 nm. The fluorescence signal rose linearly from 0 until the 45th minute of the assay. The presented data were obtained 45 min after the start of the assay. All experiments were repeated in the absence of mitochondria and background fluorescence changes were subtracted. The obtained values were normalized per mg of protein.

EPR spin-trapping measurements

Measurement of free radicals using electron paramagnetic resonance (EPR) is based on the ability of radical compounds to absorb microwave energy in strong magnetic fields. In order to demonstrate the effect of I/R and metformin on mitochondrial ROS production, an aliquot of the SMP suspension (2 mg protein) was reacted with 10 mM NADH and the spin-trapping agent – 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) – in a Quartz flat cell with a thickness of 0.5 mm. Immediately after starting the reaction, EPR spectra were recorded at an ambient temperature (25°C) using an E-540 spectrometer (Elexsys, Bruker Biospin, Germany) operating at X-band (9.7 GHz). Microwave power was 20 mV and magnetic field modulations were 1 and 4 Gauss. The quantitation of the signals’ intensities was performed by comparing the amplitude of the observed signal with the standard Mn²⁺/ZnS and Cr³⁺/MgO markers. EPR spectra were recorded as the first derivation and the main parameters – g-factor values, hyperfine coupling constant A, line widths Δ Hpp (peak-to-peak distance) and Δ App (peak-to-peak amplitude) – were calculated
according to Weil and Bolton (68). The DMPO adducts were identified according to g factor and
diphenyl-1-picrylhydrazyl (DPPH) served as an internal standard (g=2.0036). The Bruker and
Origin (Bruker, Rheistetten, Germany) software interface was used for spectra recording,
handling and evaluation (51).

31P NMR studies
Rats were anesthetized with ketamine/dormitor, the abdominal cavity was opened and a vessel
loop was loosely positioned around the porta hepatica. Spectra were scanned on the Bruker
Biospec 47/20 (4.7T field strength) animal scanner (Ettlingen, Germany) using a custom-made 10
mm loop diameter remotely-tuned 31P/1H coil. The coil consisted of two parts - a sole probe head
lying on top of the exposed liver in order to get rid of muscle tissue signals and access the portal
vein, and a remote block of tuning capacitors set approx. 10 cm apart from the probe head in
order to reduce the influence of the weight and tuning torque reaction forces of the bulky tuning
capacitors on the observed liver. During the NMR experiment, the animals lay on the back in a
holder rig with the coil on the top of the exposed liver. After acquisition of the first spectrum, the
portal vein was occluded and the subject was repositioned to the same position in the magnet.
Spectra were then acquired for the next 20 minutes. The occlusion was then released and 18 more
spectra were acquired in 5 min intervals. A single-pulse sequence without proton decoupling was
used to acquire the 31P spectra with the following parameters – TR=500 ms, 512 averages.
Relative ATP levels were then evaluated from intensities of beta ATP peaks using the jMRUI
software package (63).

Real-time quantitative PCR analysis (RT-qPCR)
Total RNA was extracted from rat liver tissue using an RNeasy Mini Kit (Qiagen, Courtaboeuf, France). 500 ng of total RNA was reverse-transcribed using a High Capacity Reverse Transcription Kit (Life Technologies, Forrest City, CA) and RT-qPCR was performed (viiA7, Life Technologies, Forrest City, CA) using EvaGreen qPCR Mix (Solis BioDyne, Estonia). The primers were designed using Primer3 software; details are given in Table 1. Gene expression values were normalized to the expression value of the housekeeping genes – Gusb and B2m. Calculations were based on the comparative cycle threshold Ct method ($2^{-\Delta\Delta Ct}$).

**Biochemical analyses**

FFA, triacylglycerol, glucose, lactate and β-hydroxybutyrate serum content were determined using commercially available kits (FFA: FFA half micro test, Roche Diagnostics, GmbH, Mannheim, Germany; triglycerides, cholesterol and glucose: ERBA-Lachema, Brno, Czech republic; β-hydroxybutyrate: Cayman Chemical Company, Ann Arbor, MI; lactate: Biovision, San Francisco, CA). Serum glucose was measured using an Accu-Chek glucometer (Roche, Czech republic). Glycogen and triacylglycerol content in the liver were determined as described previously (12).

**Statistical analyses**

Data are presented as a mean ± SEM of multiple determinations. Statistical analyses were performed using SigmaStat (Systat Software, San Jose, CA) or Microsoft Excel statistical packages. One-way ANOVA with Bonferroni or two-way ANOVA with multiple determinations was employed to test the differences between more than two groups. The Student’s t-test was
used to detect the effect of ischemia/reperfusion within groups. Differences were considered statistically significant at the level of p<0.05.

Results

3.1 Metabolic characteristics of the experimental groups

Table 2 summarizes the effects of HFD administration and metformin treatment on selected metabolic characteristics. As expected, HFD led to the elevation of serum concentrations of lactate and non-esterified fatty acids (NEFA) and to the increase in ketogenesis. Metformin had no significant effect on most of the parameters in spite of the enhanced lactate production in both SD and HFD groups. However, metformin administration resulted in diminished weight gain in the HFD group. Liver triacylglycerol (TAG) content was elevated and glycogen content reduced in the HFD group, but the effect of the diet was not reversed by metformin. In order to estimate the degree of liver injury induced by oxidative stress, we measured the serum AST and ALT activities after I/R (Table 3). As expected, I/R led to the significant increase of serum AST and ALT and this effect was more pronounced in HFD-fed animals. Metformin had no significant effect on I/R injury in SD-fed rats, but it significantly alleviated I/R-induced AST and ALT release in the HFD group.

3.2 Metformin alleviates acute oxidative stress-induced liver injury

As demonstrated by histological findings (Fig. 1A), SD-administered animals exposed to I/R developed confluent predominantly centrilobular necroses in 10% of the liver parenchyma. In HFD-fed rats, there were unevenly distributed necroses in 10-15% of the centrilobular hepatocytes in the I/R group. SD- and HFD-fed animals treated with metformin and subjected to I/R injury showed mild predominantly centrilobular steatosis without any significant

11
necroinflammatory reaction. The HFD itself increased lipid peroxidation measured as TBARS or 4-HNE content in the liver (Fig. 1B, C). For TBARS, ischemia reperfusion comparably increased lipoperoxide formation in both groups. Importantly, metformin administration diminished TBARS formation by 30% and 25% in the SD and HFD groups, respectively. 4-HNE content was increased only in the HFD, but not in the SD group subjected to I/R. Metformin mitigated the combined effect of the HFD and I/R and reduced 4–HNE content approx. 2.5 times. These results indicate that metformin protects liver tissue against acute oxidative stress in vivo, probably by preventing excessive ROS formation or strengthening the antioxidant defense.

3.3 Metformin reduces oxidative stress-induced mitochondrial damage and apoptosis in vivo

Lower oxidative stress may result in less severe mitochondrial damage in metformin-treated animals exposed to stress conditions compared with untreated ones. In the liver exposed to I/R, we found increased cytochrome c content in cytosol (SD<<HFD), suggesting its leakage from the outer mitochondrial space (Fig. 2A). This was substantially diminished in metformin-treated animals, thus indicating less mitochondrial injury. Cytosolic cytochrome c is known to trigger apoptotic cell death and we further wanted to confirm whether the reduced/increased mitochondrial damage would be reflected by the changes in the intensity of cell death executed by the apoptotic pathway. Therefore, we determined the activation of caspase 9 and its downstream target caspase 3 in liver homogenates. I/R resulted in caspase 9 and caspase 3 activations in both SD and HFD groups, the effect being more pronounced in the latter. Metformin administration eradicated (SD) or significantly attenuated (HFD) pro-apoptotic signaling in both groups (Fig. 2B,C). In order to assess whether the anti-apoptotic effect of metformin is translated into the quantitative preservation of mitochondria, we determined the activity of citrate synthase which an exclusive mitochondrial matrix enzyme. Fig. 2D
demonstrates that I/R resulted in the reduction of citrate synthase activity in both the SD and HFD groups and that the effect of I/R was prevented by metformin. The presence of mitochondrial damage and the protective effect of metformin were independently confirmed by the direct determination of mtDNA copy number in all experimental groups (Fig. 2E). In the HFD group, the effect of metformin and I/R on mitochondrial function was assessed by measuring mitochondrial respiration of NADH-dependent (Fig. 3A) and FADH-dependent substrates (Fig. 3B). In the basal state, i.e. without addition of any substrates and in the presence of malate and glutamate only (NADH-dependent substrates), we did not find any difference between the groups. In contrast, the maximal respiration rate (OCR), measured after the addition of ADP, was significantly diminished both by I/R and metformin administration, but this effect was not additive. In other words, although mitochondria from metformin-treated animals exhibited lower OCR compared with the untreated ones, they were not further damaged by the exposition to I/R. When using succinate as a substrate (FADH-dependent), the oxygen consumption rate was not affected by metformin treatment or I/R injury. Taken together, these data indicate that metformin treatment protects liver mitochondria from I/R-induced mitochondrial damage, which further ameliorates apoptosis and partly preserves mitochondrial function.

3.4 The effect of metformin on antioxidative defense status in vivo

The previous data demonstrate that metformin significantly alleviates oxidative stress evoked by the HFD itself or, more pronouncedly, in combination with I/R. Subsequently, we tested whether the effect of metformin is mediated by the increased activity of antioxidative mechanisms. In the liver, HFD administration itself was associated with diminished GSH stores and decreased activities of GPx1 and SOD, while catalase activity was up-regulated (Table 4). Metformin
treatment ameliorated some of these parameters (GSH content and SOD activity) affected by the diet alone. In the HFD group, oxidative stress evoked by I/R resulted in further exhaustion of liver GSH content and in reduction of antioxidant enzyme activity by 25-50% compared to the values in non-ischemic animals. Metformin treatment led to partial restoration of GSH content and enzyme activity. We did not observe any effect of metformin on the expression of relevant genes that encode antioxidative enzymes (not shown). The presented data demonstrate that the protective effect of metformin against oxidative damage is associated with increased activity of antioxidant systems in some stress situations.

3.5 Metformin decreases reactive oxygen species formation from succinate and NADH, but not from glycerol-3-phosphate

In principal, electron transport through the mitochondrial respiratory chain is associated with potential reactive oxygen species generation. This risk is further exacerbated during re-oxygenation after ischemia. In vitro studies identified three potential targets of the antioxidant effect of metformin – forward electron flux through complex I, reverse electron flux from complex II to complex I and mitochondrial glycerol-3-phosphate dehydrogenase (mGPDH). In vitro, utilization of NADH as the sole substrate stimulates forward electron flux, while utilization of succinate in the absence of NADH promotes reverse electron flux. In order to characterize the combined effect of in vivo metformin treatment and HFD administration on ROS formation, we used a model of submitochondrial particles (SMP). ROS production in vitro was measured using a fluorescent probe DCFDA on three different substrates – NADH as a source of electrons for complex I, glycerol-3-phosphate (G-3-P) for mGPDH and succinate for succinate dehydrogenase (Fig. 4). SMPs isolated from rats subjected to I/R without metformin treatment exhibited
significantly increased ROS production from NADH and succinate (succinate >> NADH) when compared with sham-operated controls. Previous metformin administration reduced ROS production from both these sources. No effect of metformin was observed in animals that were not exposed to I/R. Rather surprisingly, we observed no effect of either I/R or metformin on ROS production from G-3-P.

EPR spectroscopy is the only technique that can directly detect and identify different types of free radicals. We employed this method to investigate NADH-dependent ROS generation in vitro by SMPs prepared from HFD-fed groups. As shown in Fig. 5, after the addition of NADH to the SMP suspension, we were able to detect the following free radicals: organic free radical OR’, showing a symmetric singlet signal; nitrooxide radicals NO’: triplet spectrum 1:1:1; superoxide radical OOH’: quartet 1:1:1:1 and hydroxyl radical OH’: quartet 1:2:2:1, as adducts of these radicals with DMPO. The signal intensity was quantified by comparing the amplitude of the observed signal to the standard Mn²⁺/ZnS and Cr³⁺/MgO markers, the results of which are presented in Table 5. We found a significant increase in hydroxyl radical (OH’) formation in animals subjected to I/R compared with sham-operated controls. A similar trend was observed for the superoxide radical (OOH’), but it did not reach statistical significance (p=0.061). Metformin treatment had no effect on sham-operated animals but completely prevented I/R-induced generation of OOH’ and OH’ radicals (p=0.008 and 0.045, resp). Other radical species were not affected by any of the interventions. In conclusion, our data indicate that long-term metformin administration in vivo effectively prevents I/R-associated ROS production from NADH-dependent substrates and succinate.

3.6 Metformin slows down ATP synthesis in the liver in vivo
The evidence given in the previous paragraph strongly indicates that metformin administered in vivo attenuates mitochondrial respiration. If so, metformin should also affect ATP synthesis. In order to confirm this hypothesis, we measured the extent and rate of ATP repletion during reperfusion after partial liver ischemia using $^{31}$P MR spectroscopy (Fig. 6). The restraint of blood supply led to a rapid fall of ATP levels in all groups. In the SD group, ATP rapidly (within 15 min of reperfusion) resumed original values. In the HFD group, ATP content did not fully recover within examination time, reaching only approx. 80% of pre-ischemic values. The rate of ATP re-synthesis was not significantly different from the SD group. The SD and HFD curves were significantly different (p<0.05) from the 60th min until the end of the experiment. Metformin had a non-significant effect in the SD group, but the drop in ATP concentration was further emphasized in the HFD+met group compared with animals fed only a HFD. ATP content reached only 60% of initial values after reperfusion and ATP repletion in the HFD+met group was also significantly slower than for both other groups. The HFD+met and HFD curves were significantly different (p<0.05) during the first 40 min of reperfusion ($t_{20}$ – $t_{60}$).

3.7 Metformin attenuates the expression of pro-inflammatory markers in the liver

I/R injury is associated with the pro-inflammatory activation of immune cells in the liver, which is considered to be secondary to direct cellular damage resulting from ischemic insult. As we have shown, metformin reduced the I/R-induced liver injury. We further wanted to know whether this protection translated into an amelioration of pro-inflammatory status. Using RT-qPCR, we determined that the hepatic expression of pro-inflammatory markers TNFα, TLR4, IL1-β and Ccr2 was significantly higher in the liver of HFD-fed animals subjected to I/R compared with sham-operated controls and that it was significantly attenuated by metformin treatment (Fig. 7). With the exception of TLR4, we did not find this I/R-induced pro-inflammatory activation in rats
fed a standard diet. We did not observe any effect of the diet, metformin treatment or I/R injury on the expression of alternative activation markers (Arg1, Mrc1, IL-10).

The liver accommodates two different subsets of macrophages – resident macrophages (KCs) and macrophages which infiltrate the liver by circulation. The expression of markers characteristic of KCs (CD68, F4/80) was not different among the groups and did not depend on the diet or I/R injury. In contrast, the expression of Ly6c and CD11b, infiltrating monocyte and macrophage markers, resp., were significantly increased in the liver of both SD+I/R and HFD+I/R groups. Metformin treatment significantly decreased their expression and, in the case of Ly6c, even below the levels in controls. Our data suggest that long-term metformin administration alleviates I/R-induced inflammation, particularly in animals fed a HFD.

**Discussion**

Our data show that *in vivo*, metformin protects both the steatotic and normal liver from oxidative stress-related hepatotoxic injury caused by I/R. This effect is, at least in part, mediated by decreased mitochondrial ROS production resulting in reduced mitochondrial damage, attenuation of apoptotic/necrotic cell death and elimination of inflammation.

It has been previously shown that several tissues endangered by oxidative imbalance associated with T2D, particularly the myocardium (38,44), endothelial cells (5,48) and the brain (13), could be protected by metformin administration. Surprisingly, there are scarce data regarding the antioxidant effect of metformin in the fatty liver, in spite of the fact that steatosis is a hallmark of T2D and that the fatty liver is highly susceptible to oxidative stress. One study conducted on 208 Indian diabetic patients showed that metformin restores antioxidant status in plasma (24). A hepatoprotective effect of metformin (decreased serum ALT and AST levels, improved histological parameters) was proved in two small studies focused on NASH patients
Our results show that long-term metformin treatment not only alleviates chronic (HFD-induced) oxidative stress directly in liver tissue, but it also effectively protects the liver against acute and massive oxidative injury, particularly in the fatty liver. Nevertheless, the mechanism of metformin antioxidant activity is still far from clear.

The degree of oxidative stress results from the balance between the ROS formation rate and antioxidant defense capacity. Metformin is not able to scavenge superoxide radicals and is unlikely to engage in direct scavenging activity (6,33,49). In some models, antioxidative activity of metformin has been associated with its hypoglycemic effect, but in the presented study HFD-fed rats did not exhibit hyperglycemia. Numerous studies have demonstrated that both T1D (type 1 diabetes) and T2D are associated with decreased activity and expression of antioxidant enzymes and that metformin treatment can restore normal conditions (13,19,62). In our experimental design, HFD-fed rats exhibited augmented markers of oxidative stress (lipoperoxides) accompanied by a significant decrease of liver GSH content and SOD activity and elevated catalase activity. I/R further exacerbated both oxidative injury and HFD-induced dysfunction of antioxidant mechanisms. Long-term metformin treatment normalized all these markers, both in sham-operated controls and in ischemic animals.

By directly measuring ROS production using a fluorometric assay and EPR, we showed that metformin attenuates mitochondrial ROS production. In reperfused liver, ROS can be generated by several mechanisms, including xanthine/xanthine oxidase, cytosolic NADPH oxidase and the electron transport chain of mitochondria. Earlier work with rat hepatocytes using selective inhibitors has suggested that xanthine oxidase is the main generator of ROS (1). However, xanthine oxidase inhibitors employed in these studies were later recognized as mitochondrial inhibitors as well and mitochondria are now considered to be an important source of ROS within hepatocytes (28). Estimating the relative contribution of mitochondria to total...
ROS production is difficult, as it depends on actual physiological conditions, such as the ratio of resting/phosphorylating mitochondria and the capacity of reverse electron transport. In the case of the ethanol-stressed liver, where non-mitochondrial ROS production from CYP2E1 is accentuated, mitochondrial contribution has been estimated at about 22-46% (30). In hypoxia/ischemia, when the portion of non-phosphorylating mitochondria is increased and reverse electron flow accentuated, this contribution may be significantly higher.

Several production sites for ROS are recognized at the respiratory chain, including complex I (36) and complex III (35); complex I being considered crucial for the regulation of mitochondria-related ROS production (66). At complex I, the superoxide radical may be generated either by reverse electron transfer (e⁻ transport from succinate to NAD⁺ through complex I) upon succinate oxidation at complex II, or in lower amounts during forward electron transport from NADH-linked substrates (36).

In a model of a liver perfused with 10⁻²M metformin, Battandier, et al. (4) demonstrated that metformin powerfully inhibits reverse flux-related ROS production. However, these data were obtained using extremely high metformin concentrations. We are the first to demonstrate that metformin administered in vivo has the same effect, as we observed significantly decreased ROS production from succinate in submitochondrial particles isolated from metformin-treated rats subjected to I/R compared with untreated animals. Importantly, this effect persisted even when no metformin was added to the reaction in vitro. The contribution of reverse flux-related ROS generation under normoxic conditions remains questionable, but it seems to be highly relevant in hypoxia (30). This is in accordance with our results as we found the inhibitory metformin effect on ROS production from succinate only in rats that underwent I/R. Batandier, et al. (4) have shown that reverse flux-related ROS generation is very sensitive to changes in membrane potential. We have previously shown that biguanides decrease membrane potential as
a consequence of mitochondrial complex I inhibition (16). We hypothesize that this phenomenon may, at least partly, underlie metformin-dependent attenuation of reverse flux-related ROS production.

Inhibition of forward electron flux at the level of complex I by the specific inhibitor, rotenone, results in increased ROS production (46) and thus it can be assumed that metformin as a mild inhibitor of complex I may have the same effect. In contrast, we observed the inhibitory effect of metformin on NADH-dependent ROS production. This apparent contradiction could be reconciled in light of recent findings published by Matsuzaki et al. (43). Complex I has two reversible conformational states: active and deactivate (23). In its deactivated state, ROS production at complex I is significantly attenuated. Biguanides selectively inhibit the deactivated form of complex I. Consequently, this deactivation greatly enhances the sensitivity of complex I towards biguanides, forming a feedback loop that “locks” complex I in a deactivated state leading to decreased superoxide production capacity (43). Furthermore, ischemia represents a condition that promotes deactivation of complex I in vivo, thereby increasing the sensitivity to biguanide-mediated inhibition. Based on these findings, we suggest that metformin could serve as an antioxidant, particularly during oxidative stress associated with ischemia, and also following reperfusion.

Another potential source of ROS may be mGPDH, a key component of the glycerophosphate shuttle, which ensures the transport of reduced equivalents from cytosol to complex II (45). Quite recently, mGPDH was recognized as a new target of metformin (40). Its contribution to ROS production has been documented in brown adipose tissue (65), but no data concerning liver mitochondria are available. In our study, the contribution of ROS produced by G-3-P was significantly lower than from succinate. It also failed to respond to I/R and metformin.
Given that mGPDH expression in the liver is very low (34), we do not consider this enzyme to be an important target of metformin antioxidant activity.

The accumulation of intracellular ROS induces cell death and, during hepatic I/R, hepatocytes undergo both apoptosis and necrosis (56). Some studies have suggested apoptosis to be the primary mode of death (55), while others have reported necrosis (61). In the present study, we found signs of both necroinflammation and on-going apoptosis in the liver tissue of rats subjected to I/R, where the effect was more pronounced in the HFD group. We can explain the beneficial effect of metformin on both forms of cell death as the consequence of lower mitochondrial ROS production.

In the liver of metformin-treated animals, we observed lower expression of pro-inflammatory as well as infiltrating monocyte/macrophage markers two days after short-term ischemia, which points to the possible anti-inflammatory effect of metformin. The direct anti-inflammatory action of metformin has been reported in several animal experimental studies, both in the liver (69,54,47) and in circulating polymorphonuclear cells (9). In contrast to these experimental findings, metformin efficiency in human NASH treatment is the subject of open debate (58,60). The beneficial effect of metformin in our study could be explained either by the direct effect of metformin on KCs or by the attenuation of intracellular ROS production in hepatocytes, resulting in diminished necrosis and suppressed inflammation.

Many reports demonstrated that ROS are important modulators of signaling pathways and the intensity of their production seems to be a key factor in discriminating between cell death and survival (53,25,39). It has been suggested that ROS act as second messengers that promote sustained activation of c-Jun N-terminal kinase (JNK) and apoptotic signaling (59). Furthermore, they also have been shown to inhibit NF-κB by preventing transcription of survival genes (26).

During reperfusion after ischemia, Kupffer cells generate ROS, which in turn activate JNK at
least in part through the ROS-dependent ASK1 (apoptosis signal-regulating kinase 1) pathway
and enhance secretion of various chemokines and cytokines including TNFα (57). TNFα may
serve as a potent activator of either pro-survival or pro-apoptotic pathways (15) and some authors
even report that it is a critical mediator in warm hepatic IR injury (64). TNFα released from
Kupffer cells may activate TNF receptors on hepatocytes, which induce JNK activation as well as
ROS production. JNK activation results in the activation of its down-stream targets, i.e. AP-1
family members c-Jun, ATF-2 and JunD, which are involved in the regulation of inflammation,
proliferation and cell death (57). In addition, ROS oxidize and inactivates MAPK phosphatases,
which dephosphorylate JNK, leading to its prolonged activation and augmentation of apoptosis
(31). In the present study we showed data indicating that metformin reduces mitochondrial ROS
production and we hypothesize that the attenuation of ROS signaling may explain, at least partly,
the protective effect of metformin in IR. Another mechanism contributing to the reduction of
inflammation in metformin-treated animals may be the reduction of ROS-induced lipoperoxide
products formation during early reperfusion phase. These products are potent chemotactic factors
for neutrophils and are the determining factor for the continuation of neutrophil recruitment and
aggravation of injury (29). In accordance with this supposition we observed a significantly lower
expression of infiltrating macrophages markers in metformin-treated animals subjected to IR.

Attenuation of mitochondrial respiration compromises the hepatocyte energy state. Foretz,
et al. (17) have shown that metformin decreases ATP content in a dose-dependent manner, both
in primary hepatocytes and in the liver after metformin administration in vivo. Using direct 31P-
NMR measurements in vivo, we demonstrated that long-term metformin treatment decreased
ATP repletion during reperfusion, both in terms of rate and relative quantity. As we have
previously shown (16), metformin does not function as an uncoupler and thus the decrease in
ATP content reflects the weaker performance of the mitochondrial respiratory chain. Low ATP
availability is generally an unfavorable condition and may contribute to high-dose metformin
toxicity, but we suggest that under conditions of acute oxidative stress the beneficial
consequences of diminished electron flux through the respiratory chain, i.e. lower ROS
formation, outweighs the disadvantages of compromised energy production.

In conclusion, we demonstrate that metformin protects the fatty liver from acute oxidative
stress-related mitochondrial injury and cell death. We propose that the beneficial effect of
metformin action is based on the combination of three contributory mechanisms: increase of
antioxidant enzyme activity, lower mitochondrial ROS production at complex I and reduction of
post-ischemic inflammation. The presented data support the extension of the therapeutic
application of metformin as an antioxidant, particularly during ischemia/reperfusion-related
oxidative stress.

Acknowledgement
We thank M. Jirsa, MD, PhD (Institute for Clinical and Experimental Medicine, Czech Republic)
for his critical reading and discussion of the manuscript.

Disclosures
The authors declare that there is no conflict of interest associated with this manuscript.

Grants
This study was supported by MH CR-DRO (“Institute for Clinical and Experimental Medicine –
IKEM, IN 00023001”), grant no. LL 1204 (within the ERC CZ program), grant no. OPPK
MitEnAl cz.2.16/3.1.00/21531 and by the research project PRVOUK P37/02 from the Ministry of
Education, Youth and Sports, CR.
Authors’ Contributions

All authors substantially contributed to this study. M.C. designed the experiments, analyzed the data, discussed the manuscript, coordinated and directed the project, developed the hypothesis and wrote the manuscript. E.P. designed and performed the experiments, analyzed the data and discussed and wrote the manuscript. E.S., O.O., Z.P., L.K. and H.D. performed the experiments, analyzed the data and discussed the manuscript. M.B. and C.G. were responsible for the MR measurements. P.S. and J.K. made EPR measurements. Z.D. and E.P. performed the in vitro mitochondria experiments. Z.C. and O.K. designed the experiments and discussed the manuscript. All authors approved the final version of the manuscript. M.C. is responsible for the integrity of the work as a whole.

References


Figure captions

Figure 1 Effect of metformin on liver injury induced by ischemia/reperfusion. (A) Confluent necroses of hepatocytes were observed in animals fed a SD and HFD after I/R injury (the dashed lines delimit the necrotic areas); no necroinflammatory activity was observed in sham-operated controls and in the SD+I/R and HFD+I/R groups treated with metformin. Hematoxylin and eosin staining, original magnification x 100. The lipoperoxide formation was determined according to TBARS (B) and 4-HNE content (C). Data are presented as a mean ± SEM, n=10. Bars marked with the same letter are statistically significantly different, b,c,d,f,h,j p < 0.05; a,e,g,k,l p < 0.01.

Figure 2 Effect of metformin on oxidative stress-induced mitochondrial damage and apoptosis in rats subjected to ischemia/reperfusion. A: Cytochrome c release to cytosol estimated according to the abundance of cytochrome c in the freshly prepared post-mitochondrial fraction. Cyt c band intensity was normalized to actin and expressed as cyt c : actin ratio. B,C: caspase 9 (B) and caspase 3 (C) activation. The signal intensities corresponding to the full-length proteins and cleaved fragments (caspase 9: 51, 40 and 38 kDa; caspase 3: 35 and 17 kDa) were assessed by densitometry. The graphs show the ratio of cleaved fragments / full-length protein density. D: citrate synthase activity in the liver homogenate; E: mitochondrial DNA copy number per cell in the liver. Data are presented as a mean ± SEM, n=10. Bars marked with the same letter are statistically significantly different; a,b,c,d,h,l,n,o,s,u,v,x p < 0.05; e,m,p,r,t,w p < 0.01; f,g,i,j,k p < 0.001.

Figure 3 Mitochondrial respiration of NADH-dependent (A) and FADH-dependent (B) substrates. Liver mitochondria were isolated from rats fed HFD -/+ metformin, half of the animals in each group (n=5) being subjected to I/R as described in Methods. The oxygen consumption rate of isolated liver mitochondria (10 ug protein per well) was monitored on an XF
Analyzer in the presence of chemicals added at time intervals shown on the graph. The additions included 5 mM malate (M), 10 mM glutamate (G), 4 mM ADP, 2 µM rotenone and 10 mM succinate (final concentrations). Data are presented as a mean ± SEM. The maximal respiration rate (M+G+ADP) was statistically significantly higher in HFD compared with all other groups.

**Figure 4** *ROS production from different substrates in submitochondrial particles.* SMPs were prepared from liver mitochondria of rats fed HFD -/+ metformin, half of the animals in each group being subjected to I/R as described in Methods. ROS production in mitochondria was measured by DCFDA (10 µM) in the presence of either 10 mM NADH (A), 10 mM glycerol-3-P (B) or 10 mM succinate (C). The values represent fluorescence units and are normalized per 1 mg of mitochondrial protein. Data are presented as a mean ± SEM, n=5. Bars marked with the same letter are statistically significantly different; a,b,d p < 0.05; c p < 0.01.

**Figure 5** *Typical EPR spectra obtained after addition of NADH (10 mM) to the suspension of SMP using DMPO as a spin-trapping agent.* The DMPO adducts were identified according to their g factor and DPPH served as an internal standard (g=2.0036). OOH’ and OH’ radicals were distinguished by detailed analysis of overlapping OOH’ and OH’ signals using computer simulation. OR’ organic free radical; NO’ nitroxide radicals; OOH’ superoxide radical; OH’ hydroxyl radical; DPPH diphenyl-1-picrylhydrazyl.

**Figure 6** *Effect of long-term metformin administration on ATP re-synthesis during reperfusion after partial ischemia.* The partial ischemia was induced by portal vein ligation (time 0) and released 20 min later (time 20). The measurement continued in 5 min intervals. Liver ATP
content was determined using $^{31}$P-NMR spectroscopy. The data are expressed as the relative change compared with the respective value in “time 0” and presented as a mean ± SEM, n=10. The statistical significance of the course of the curves was tested by two-way ANOVA with repeated measurements.

**Figure 7** Effect of metformin on the relative expression of pro- and anti-inflammatory markers in the liver. The expression of individual mRNAs was determined by RT-qPCR. Data are expressed as a fold change related to the untreated SD group. Values are given as a mean ± SEM, n=5. Bars marked with the same letter are statistically significantly different; a,b,c,f,g,h,i,j,k,l,o,r,s,t,u $p < 0.05$; d,e,m,n,p $p < 0.01$; v $p < 0.001$. 
<table>
<thead>
<tr>
<th>Gene</th>
<th>NCBI Ref. Seq.</th>
<th>Forward primer</th>
<th>Reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arg 1</td>
<td>M_017134.1</td>
<td>CTGCTGGGAAGGAAGAAAAG</td>
<td>TTCCCAAGAGTTGAGGTCAC</td>
</tr>
<tr>
<td>CD68</td>
<td>NM_001031638.1</td>
<td>CAAGCAGCACAGTGGACATTC</td>
<td>GCCAGCAAGAGAGATGGTC</td>
</tr>
<tr>
<td>Emr1</td>
<td>NM_001007557.1</td>
<td>CAACGCCAGGTACGAGATG</td>
<td>TGCCGCAACTAACGATACC</td>
</tr>
<tr>
<td>Mrc1</td>
<td>NM_001106123.1</td>
<td>CAACCAAAGCTGACGAGATG</td>
<td>AGGTGGGCTCTTGAGGTATG</td>
</tr>
<tr>
<td>TLR4</td>
<td>NM_019178.1</td>
<td>GGATTTATCCAGGATGGAAAATTC</td>
<td>GCTTCACAGGCCACAGATT</td>
</tr>
<tr>
<td>Osp</td>
<td>NM_012881.2</td>
<td>TGATGAAAGAATACGAGATG</td>
<td>TGTTCCATCCAGCTGACTTG</td>
</tr>
<tr>
<td>Ccr 2</td>
<td>NM_021866.1</td>
<td>TTGTGATCTGGCACTCTACTTG</td>
<td>AACGCGAGCAGTGCTGATTC</td>
</tr>
<tr>
<td>IL10</td>
<td>NM_012854.2</td>
<td>CGCAGGACTTAAAGGGTACTTG</td>
<td>TTTCACAGGGAGAATTCG</td>
</tr>
<tr>
<td>Cd11b</td>
<td>NM_012711.1</td>
<td>CTCTCCGAGAACCCTCTCAAG</td>
<td>ATGCAGGACTTAAAGGGAG</td>
</tr>
<tr>
<td>IL1 beta</td>
<td>NM_031512.2</td>
<td>AGTCTGGCACAGTTCCCCAAC</td>
<td>GAGACCTGACTTGGCAAGAG</td>
</tr>
<tr>
<td>Ly6-C</td>
<td>NM_020103.1</td>
<td>GTGTGCAGAAGAGCTCAAG</td>
<td>ATGGCAACAGGAAACCTTCG</td>
</tr>
<tr>
<td>Tgf1b</td>
<td>NM_021578.2</td>
<td>ACTGCTTCAGCTCCACAGAG</td>
<td>TGTTGTAGAGGGCAAGAGC</td>
</tr>
<tr>
<td>TNF a</td>
<td>NM_012675.3</td>
<td>CAAGGAGGAGAAGTTCCCCAATG</td>
<td>GCTGGTGTGGTCTGACGAC</td>
</tr>
<tr>
<td>mtNd5</td>
<td>NC_001665.2</td>
<td>GACTACTAATTGCCAGGCCACAGGAA</td>
<td>TAGTAGGGCAGAGGGAGATTG</td>
</tr>
<tr>
<td>Ucp 2</td>
<td>NC_005100.4</td>
<td>AGAACGAGGACACCTTTAGAGA</td>
<td>TGCCGAGTTCTCACTACAC</td>
</tr>
</tbody>
</table>
Table 2 Metabolic characteristics of the experimental groups.

<table>
<thead>
<tr>
<th></th>
<th>SD</th>
<th>SD + met</th>
<th>HFD</th>
<th>HFD + met</th>
</tr>
</thead>
<tbody>
<tr>
<td>body weight g</td>
<td>482±9</td>
<td>466±12</td>
<td>490±7&lt;sup&gt;i&lt;/sup&gt;</td>
<td>437±10&lt;sup&gt;i&lt;/sup&gt;</td>
</tr>
<tr>
<td>metformin µmol . l&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>-</td>
<td>6.8±0.8</td>
<td>-</td>
<td>6.1±1</td>
</tr>
<tr>
<td>glycemia mmol . l&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>6.4±0.1</td>
<td>6.2±0.2</td>
<td>6.1±0.1</td>
<td>6.3±0.1</td>
</tr>
<tr>
<td>lactate mmol . l&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>3.5±0.2&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>4.7±0.3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>5.9±0.5&lt;sup&gt;b,j&lt;/sup&gt;</td>
<td>6.7±0.3&lt;sup&gt;j&lt;/sup&gt;</td>
</tr>
<tr>
<td>triacylglycerol mmol . l&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>1.8±0.09&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.8±0.2</td>
<td>1.4±0.12&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.5±0.2</td>
</tr>
<tr>
<td>FFA mmol . l&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>0.75±0.05&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.81±0.04</td>
<td>1.02±0.05&lt;sup&gt;d&lt;/sup&gt;</td>
<td>0.91±0.1</td>
</tr>
<tr>
<td>cholesterol mmol . l&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>1.6±0.11</td>
<td>1.4±0.13</td>
<td>1.5±0.17</td>
<td>1.6±0.1</td>
</tr>
<tr>
<td>β-OH butyrate mmol . l&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>0.17±0.2&lt;sup&gt;e&lt;/sup&gt;</td>
<td>0.23±0.01</td>
<td>0.94±0.2&lt;sup&gt;e&lt;/sup&gt;</td>
<td>1.03±0.03</td>
</tr>
<tr>
<td>triacylglycerol µmol . g&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>12.0±1.3&lt;sup&gt;f,g&lt;/sup&gt;</td>
<td>9.1±1.1&lt;sup&gt;f&lt;/sup&gt;</td>
<td>60.5±11.3&lt;sup&gt;g&lt;/sup&gt;</td>
<td>53.9±8.6</td>
</tr>
<tr>
<td>glycogen µmol glucose . g&lt;sup&gt;-1&lt;/sup&gt;</td>
<td>280±13&lt;sup&gt;h&lt;/sup&gt;</td>
<td>277±20</td>
<td>219±28&lt;sup&gt;b&lt;/sup&gt;</td>
<td>185±14</td>
</tr>
</tbody>
</table>

All parameters were determined in the serum or liver of fed animals. Data are expressed as a mean ± SEM. Serum parameters: n = 20 per group (blood was collected prior operation); liver parameters: n = 10 per group (only sham-operated animals). FFA = free fatty acids. Values marked with the same letter are statistically significantly different; <sup>a,c,d,j</sup> p < 0.05; <sup>b,h,i</sup> p < 0.01; <sup>e,f,g</sup> p < 0.001.
Table 3 Effect of ischemia reperfusion on the markers of liver injury.

<table>
<thead>
<tr>
<th></th>
<th>SD</th>
<th>SD+met</th>
<th>HFD</th>
<th>HFD+met</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AST</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>μkat . l⁻¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>control</td>
<td>3.7±0.2ᵃ</td>
<td>3.8±0.1ᵇ</td>
<td>4.1±0.3ᶜ</td>
<td>3.9±0.5ᵉ</td>
</tr>
<tr>
<td>I/R</td>
<td>7.0±0.3ᵃ</td>
<td>6.8±0.3ᵇ</td>
<td>12.6±1.5ᶜᵈ</td>
<td>7.0±0.8ᵈᵉ</td>
</tr>
<tr>
<td><strong>ALT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>μkat . l⁻¹</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>control</td>
<td>0.8±0.1</td>
<td>0.7±0.1</td>
<td>1.0±0.1ᶠ</td>
<td>0.7±0.1ʰ</td>
</tr>
<tr>
<td>I/R</td>
<td>1.1±0.2</td>
<td>1.0±0.3</td>
<td>4.1±0.8ᵍʰ</td>
<td>2.0±0.7ᵍʰ</td>
</tr>
</tbody>
</table>

Data are expressed as a mean ± SEM, n=10. Values marked with the same letter are statistically significantly different; ᵍ p < 0.05; ᵈ,ᵉ p < 0.01; ᵃ,b,c,f p < 0.001.
Table 4: GSH concentration and antioxidant enzyme activities in the liver of rats exposed to ischemia/reperfusion.

<table>
<thead>
<tr>
<th></th>
<th>SD</th>
<th>SD+met</th>
<th>HFD</th>
<th>HFD+met</th>
</tr>
</thead>
<tbody>
<tr>
<td>GSH</td>
<td>control</td>
<td>7±0.14a</td>
<td>6.8±0.2</td>
<td>4.3±0.1j</td>
</tr>
<tr>
<td></td>
<td>I/R</td>
<td>4.3±0.4b</td>
<td>4.6±0.3</td>
<td>1.7±0.2k</td>
</tr>
<tr>
<td>GSH-Px</td>
<td>control</td>
<td>540±30c</td>
<td>583±45</td>
<td>414±22e</td>
</tr>
<tr>
<td></td>
<td>I/R</td>
<td>428±22d</td>
<td>429±25</td>
<td>258±20d,l</td>
</tr>
<tr>
<td>Catalase</td>
<td>control</td>
<td>758±26e</td>
<td>820±51</td>
<td>947±13e</td>
</tr>
<tr>
<td></td>
<td>I/R</td>
<td>693±33f</td>
<td>729±49</td>
<td>508±29f,m</td>
</tr>
<tr>
<td>SOD</td>
<td>control</td>
<td>143±10g</td>
<td>156±5</td>
<td>91±3g,n</td>
</tr>
<tr>
<td></td>
<td>I/R</td>
<td>95±5b,i</td>
<td>138±6b</td>
<td>73±5i,o</td>
</tr>
</tbody>
</table>

GSH content was determined in the isolated mitochondria; all other parameters were determined in the whole liver homogenate. Data are expressed as a mean ± SEM, n=10. Values marked with the same letter are statistically significantly different; e,f,i,j,n p < 0.05; b,c,g,h,l,o p < 0.01; a,d,h,m p < 0.001.
Table 5 *Free radical generation in submitochondrial particles in vitro.*

<table>
<thead>
<tr>
<th></th>
<th>HFD</th>
<th>HFD+met</th>
<th>HFD+I/R</th>
<th>HFD+met+I/R</th>
</tr>
</thead>
<tbody>
<tr>
<td>free organic radical</td>
<td>7.9±1.1</td>
<td>7.9±0.3</td>
<td>7.6±0.8</td>
<td>6.9±0.3</td>
</tr>
<tr>
<td>nitrosyl radical NO.</td>
<td>3.8±0.8</td>
<td>4.1±0.2</td>
<td>4.3±0.5</td>
<td>4.2±0.6</td>
</tr>
<tr>
<td>superoxide radical OOH.</td>
<td>4.1±0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.0±0.25</td>
<td>5.1±0.3&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>3.3±0.4&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>hydroxyl radical OH.</td>
<td>1.2±0.03&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.1±0.1</td>
<td>1.7±0.2&lt;sup&gt;c,d&lt;/sup&gt;</td>
<td>1.2±0.05&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

SMPs prepared from liver mitochondria were isolated from rats fed HFD +/- metformin, half of the animals in each group being subjected to I/R as described in Methods. ROS production in mitochondria was measured by EPR spectroscopy with 10 mM NADH as a substrate. Data are expressed as a mean ± SEM, n=5. Values marked with the same letter are statistically significantly different; <sup>a,b,c,d</sup> p < 0.05.
Figure 1

A

sham

I/R

SD  SD + met  HFD  HFD + met

B

TBARS

C

4-HNE

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
<table>
<thead>
<tr>
<th>Gene</th>
<th>NCBI Ref. Seq.</th>
<th>Forward primer</th>
<th>Reverse primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arg 1</td>
<td>M_017134.1</td>
<td>CTGCTGGGAAGGAAGAAAAG</td>
<td>TTCCCAAGAGTGTTGGTTCAC</td>
</tr>
<tr>
<td>CD68</td>
<td>NM_001031638.1</td>
<td>CAAAGCAGCACAGTGACATTTC</td>
<td>GGCAGCAAGAGAGATTGGTTC</td>
</tr>
<tr>
<td>Emr1</td>
<td>NM_001007557.1</td>
<td>CAACCGCAGGAGGAGATG</td>
<td>TGCAGCCAAGATACGAGATCC</td>
</tr>
<tr>
<td>Mrc1</td>
<td>NM_001106123.1</td>
<td>CAAGCAGACCGTACCAAGG</td>
<td>AGGTTGGGCTTCATTGGTATG</td>
</tr>
<tr>
<td>TLR4</td>
<td>NM_019178.1</td>
<td>GGATTTATCCAGGTGTGAATTTG</td>
<td>GCTCCACAGCCACAGCATG</td>
</tr>
<tr>
<td>Osp</td>
<td>NM_012881.2</td>
<td>CTGATGAACAGATACCCGATG</td>
<td>TGGTTCACTCCAGCTGACTTG</td>
</tr>
<tr>
<td>Ccr 2</td>
<td>NM_021866.1</td>
<td>TTTTATCCCTGAGGCCTTTTG</td>
<td>AACGCAGAGTGTGTCATT</td>
</tr>
<tr>
<td>IL10</td>
<td>NM_012854.2</td>
<td>GGCAAGACTTTAAGGGTTACTTG</td>
<td>TTCTCAAGGGGAGAAATCG</td>
</tr>
<tr>
<td>Cd11b</td>
<td>NM_012711.1</td>
<td>CTTCCTCAGAAACCTCTCAAG</td>
<td>ATGCGGAGTCGTGTTAAAGAG</td>
</tr>
<tr>
<td>IL1 beta</td>
<td>NM_031512.2</td>
<td>AATCTGTGGACAGTTCCCAC</td>
<td>GAGACCTGACTGGGAGAG</td>
</tr>
<tr>
<td>Ly6-C</td>
<td>NM_020103.1</td>
<td>GTGTCGAGAAAGAGCTCAGG</td>
<td>AGTAGCAACAGGAACCTCAG</td>
</tr>
<tr>
<td>Tgf1b</td>
<td>NM_021578.2</td>
<td>ACTTTCTCAGACTCCACAGAG</td>
<td>TGGTTGTAGAGGCAAGGAC</td>
</tr>
<tr>
<td>TNF a</td>
<td>NM_012675.3</td>
<td>CTTAGGGAGAAAGTTTCCAAAAG</td>
<td>GCTTGGGCTTTTGTACACG</td>
</tr>
<tr>
<td>mtNd5</td>
<td>NC_001665.2</td>
<td>GACTTAATTGACGCAAGAAGA</td>
<td>GATAGTAGGAAGAGACGGAGT</td>
</tr>
<tr>
<td>Ucp 2</td>
<td>NC_005100.4</td>
<td>AAGAAGGGAGACACTTTGAGA</td>
<td>TGGCCCAGGTTCCATCACAC</td>
</tr>
</tbody>
</table>

Table 1
<table>
<thead>
<tr>
<th></th>
<th>SD</th>
<th>SD + met</th>
<th>HFD</th>
<th>HFD + met</th>
</tr>
</thead>
<tbody>
<tr>
<td>body weight g</td>
<td>482±9</td>
<td>466±12</td>
<td>490±7</td>
<td>437±10</td>
</tr>
<tr>
<td>metformin μmol·l⁻¹</td>
<td>-</td>
<td>6.8±0.8</td>
<td>-</td>
<td>6.1±1</td>
</tr>
<tr>
<td>glycemia mmol·l⁻¹</td>
<td>6.4±0.1</td>
<td>6.2±0.2</td>
<td>6.1±0.1</td>
<td>6.3±0.1</td>
</tr>
<tr>
<td>lactate mmol·l⁻¹</td>
<td>3.5±0.2ᵃᵇ</td>
<td>4.7±0.3ᵃ</td>
<td>5.9±0.5ᵇ⁻ʲ</td>
<td>6.7±0.3ˡ</td>
</tr>
<tr>
<td>triacylglycerol mmol·l⁻¹</td>
<td>1.8±0.09ᶜ</td>
<td>1.8±0.2</td>
<td>1.4±0.12ᶜ</td>
<td>1.5±0.2</td>
</tr>
<tr>
<td>FFA mmol·l⁻¹</td>
<td>0.75±0.05ᵈ</td>
<td>0.81±0.04</td>
<td>1.02±0.05ᵈ</td>
<td>0.91±0.1</td>
</tr>
<tr>
<td>cholesterol mmol·l⁻¹</td>
<td>1.6±0.11</td>
<td>1.4±0.13</td>
<td>1.5±0.17</td>
<td>1.6±0.1</td>
</tr>
<tr>
<td>β-OH butyrate mmol·l⁻¹</td>
<td>0.17±0.2ᶜ</td>
<td>0.23±0.01</td>
<td>0.94±0.2ᶜ</td>
<td>1.03±0.03</td>
</tr>
<tr>
<td>liver</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>triacylglycerol μmol·g⁻¹</td>
<td>12.0±1.3ᶠᵍ</td>
<td>9.1±1.1ᶠ</td>
<td>60.5±11.3ᵍ</td>
<td>53.9±8.6</td>
</tr>
<tr>
<td>glycogen μmol glucose·g⁻¹</td>
<td>280±13ʰ</td>
<td>277±20</td>
<td>219±28ʰ</td>
<td>185±14</td>
</tr>
</tbody>
</table>

Table 2
<table>
<thead>
<tr>
<th></th>
<th>SD</th>
<th>SD+met</th>
<th>HFD</th>
<th>HFD+met</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST μkat. l⁻¹</td>
<td>control</td>
<td>3.7±0.2a</td>
<td>3.8±0.1b</td>
<td>4.1±0.3c</td>
</tr>
<tr>
<td></td>
<td>I/R</td>
<td>7.0±0.3a</td>
<td>6.8±0.3b</td>
<td>12.6±1.5c,d</td>
</tr>
<tr>
<td>ALT μkat. l⁻¹</td>
<td>control</td>
<td>0.8±0.1</td>
<td>0.7±0.1</td>
<td>1.0±0.1f</td>
</tr>
<tr>
<td></td>
<td>I/R</td>
<td>1.1±0.2</td>
<td>1.0±0.3</td>
<td>4.1±0.8f,g</td>
</tr>
</tbody>
</table>

Table 3
<table>
<thead>
<tr>
<th></th>
<th>SD</th>
<th>SD+met</th>
<th>HFD</th>
<th>HFD+met</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GSH</strong></td>
<td><strong>control</strong></td>
<td>7±0.14(^a)</td>
<td>6.8±0.2</td>
<td>4.3±0.1(^{a,j})</td>
</tr>
<tr>
<td>mM/ mg prot(^{-1})</td>
<td><strong>I/R</strong></td>
<td>4.3±0.4(^b)</td>
<td>4.6±0.3</td>
<td>1.7±0.2(^{b,k})</td>
</tr>
<tr>
<td><strong>GSH-Px</strong></td>
<td><strong>control</strong></td>
<td>540±30(^c)</td>
<td>583±45</td>
<td>414±22(^{c,e})</td>
</tr>
<tr>
<td>µM GSH . min(^{-1}). mg prot(^{-1})</td>
<td><strong>I/R</strong></td>
<td>428±22(^d)</td>
<td>429±25</td>
<td>258±20(^{l,i})</td>
</tr>
<tr>
<td><strong>Catalase</strong></td>
<td><strong>control</strong></td>
<td>758±26(^e)</td>
<td>820±51</td>
<td>947±13(^{e,g})</td>
</tr>
<tr>
<td>µM H(_2)O(_2) . min(^{-1}). mg prot(^{-1})</td>
<td><strong>I/R</strong></td>
<td>693±33(^f)</td>
<td>729±49</td>
<td>508±29(^{l,m})</td>
</tr>
<tr>
<td><strong>SOD</strong></td>
<td><strong>control</strong></td>
<td>143±10(^g)</td>
<td>156±5</td>
<td>91±3(^{g,n})</td>
</tr>
<tr>
<td>µU/ mg prot(^{-1})</td>
<td><strong>I/R</strong></td>
<td>95±5(^h,i)</td>
<td>138±6(^h)</td>
<td>73±5(^{i,o})</td>
</tr>
</tbody>
</table>

**Table 4**
<table>
<thead>
<tr>
<th></th>
<th>HFD</th>
<th>HFD+met</th>
<th>HFD+I/R</th>
<th>HFD+met+I/R</th>
</tr>
</thead>
<tbody>
<tr>
<td>free organic radical</td>
<td>7.9±1.1</td>
<td>7.9±00.3</td>
<td>7.6±0.8</td>
<td>6.9±0.3</td>
</tr>
<tr>
<td>nitrosyl radical NO.</td>
<td>3.8±0.8</td>
<td>4.1±0.2</td>
<td>4.3±0.5</td>
<td>4.2±0.6</td>
</tr>
<tr>
<td>superoxide radical OOH.</td>
<td>4.1±0.2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>4.0±0.25</td>
<td>5.1±0.3&lt;sup&gt;a,b&lt;/sup&gt;</td>
<td>3.3±0.4&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>hydroxyl radical OH.</td>
<td>1.2±0.03&lt;sup&gt;c&lt;/sup&gt;</td>
<td>1.1±0.1</td>
<td>1.7±0.2&lt;sup&gt;c,d&lt;/sup&gt;</td>
<td>1.2±0.05&lt;sup&gt;d&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

**Table 5**